Latest Content

Daisy Molina, EdD, MSN, RNC-LRN, explains how nurses can include caregivers in breast cancer care while keeping the patient's voice central.

In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.

Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.

FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma.

Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.

A COA survey found inconsistent coverage and upfront costs top the barriers to cellular therapy in independent community oncology practices.

Daisy Molina, EdD, MSN, RNC-LRN, details how nursing students learn to deliver hard news with empathy, plain language, and team support.

Among 90 patients with ES-SCLC, all CRS in the outpatient cohort was grade 1, and no patient in any care model was readmitted.

At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.

Kate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.

By 26 months, 81% of families of children with B-ALL reported job or marital changes; less frequent maintenance pulses eased expenses only.

Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.